Astrazeneca Phar

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
6,158.50
38.05 (0.62%)
BSENSE

Nov 20

BSE+NSE Vol: 11.08 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Corona Remedies
Alivus Life
Marksans Pharma
Caplin Point Lab
Sudeep Pharma
Astrazeneca Phar
Cohance Life
Concord Biotech
Jubilant Pharmo
Pfizer
Natco Pharma
Why is Astrazeneca Pharma India Ltd ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 22.81%
  • Company has a low Debt to Equity ratio (avg) at 0 times
2
Positive results in Sep 26
  • DPS(Y) Highest at Rs 36.00
  • CASH AND CASH EQUIVALENTS(HY) Highest at Rs 575.14 cr
  • NET SALES(Q) Highest at Rs 729.10 cr
3
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 13-Nov-26 and has generated 1.98% returns since then
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
With ROE of 21.4, it has a Very Expensive valuation with a 17.5 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -32.41%, its profits have fallen by -18.9%
5
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 0.97% over the previous quarter and collectively hold 9.73% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Astrazeneca Phar should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Astrazeneca Phar for you?

Low Risk, Low Return

Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
-32.41%
-1.31
24.72%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
27.13%
EBIT Growth (5y)
22.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.14
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
2.01
Tax Ratio
27.14%
Dividend Payout Ratio
47.99%
Pledged Shares
0
Institutional Holding
9.73%
ROCE (avg)
91.83%
ROE (avg)
22.81%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
82
Industry P/E
40
Price to Book Value
17.48
EV to EBIT
64.65
EV to EBITDA
59.47
EV to Capital Employed
37.21
EV to Sales
5.72
PEG Ratio
NA
Dividend Yield
0.59%
ROCE (Latest)
57.56%
ROE (Latest)
21.42%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company
DPS(Y)

Highest at Rs 36.00

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 575.14 cr

NET SALES(Q)

Highest at Rs 729.10 cr

PBDIT(Q)

Highest at Rs 95.57 cr.

PBT LESS OI(Q)

Highest at Rs 88.33 cr.

PAT(Q)

Highest at Rs 72.87 cr.

EPS(Q)

Highest at Rs 24.93

-2What is not working for the Company
OPERATING CF(Y)

Lowest at Rs -15.14 Cr

Loading Valuation Snapshot...
Here's what is working for Astrazeneca Phar
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 88.33 cr has Grown at 70.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 51.73 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 72.87 cr has Grown at 68.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 43.38 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Dividend per Share (DPS) - Annually
Highest at Rs 36.00 and Grown
each year in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (Rs)

Net Sales - Quarterly
Highest at Rs 729.10 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 95.57 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 88.33 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 72.87 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 24.93
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Cash and Cash Equivalents - Half Yearly
Highest at Rs 575.14 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Astrazeneca Phar
Operating Cash Flow - Annually
Lowest at Rs -15.14 Cr
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Non Operating Income - Quarterly
Highest at Rs 15.12 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income